Evidence map›Paper›PMID 35179509›Full record

ArticleJournal of medical Internet research2022

Acceptability of and Willingness to Take Digital Pills by Patients, the Public, and Health Care Professionals: Qualitative Content Analysis of a Large Online Survey.

Astrid Chevance, Axel Fortel, Adeline Jouannin, Faustine Denis, Marie-France Mamzer, Philippe Ravaud, Stephanie Sidorkiewicz

Open access · goldAbstract read
In one paragraph

Article in Journal of medical Internet research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Adoption of Digital Therapeutics in Europe.Therapeutics and clinical risk management · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Astrid ChevanceCenter for Research in Epidemiology and Statistics, Université de Paris-French National Institute for Health and Medical Research, Paris, France.ORCID 0000-0002-0852-4322
Axel FortelFaculté de médecine de Créteil, Université Paris-Est-Créteil, Créteil, France.ORCID 0000-0002-3252-0292
Adeline JouanninDépartement de Médecine Générale, Université de Rennes, Rennes, France.ORCID 0000-0002-7040-0582
Faustine DenisDepartment of Psychiatry, Groupe Hospitalo-Universitaire Paris Psychiatrie Neurosciences, Paris, France.ORCID 0000-0001-8004-8722
Marie-France MamzerDepartment of Ethics, Research, Translations, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, French National Institute for Health and Medical Research, Paris, France.ORCID 0000-0001-7570-1803
Philippe RavaudCenter for Research in Epidemiology and Statistics, Université de Paris-French National Institute for Health and Medical Research, Paris, France.ORCID 0000-0001-8264-9206
Stephanie SidorkiewiczCenter for Research in Epidemiology and Statistics, Université de Paris-French National Institute for Health and Medical Research, Paris, France.ORCID 0000-0002-4720-927X
Université Paris Cité · FRFHU Neurovasc · FRHôpital Necker-Enfants Malades · FRUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDigital pills are pills combined with a sensor, which sends a signal to a patch connected to a smartphone when the pills are ingested. Health care professionals can access patient data from digital pills online via their own interface, thus allowing them to check whether a patient took the drug. Digital pills were developed for the stated goal of improving treatment adherence. The US Food and Drug Administration approved the first digital pills in November 2017, but the manufacturer withdrew its application to the European Medicines Agency in July 2020 because of insufficient evaluation.

objectiveAs recommended for the evaluation of health technologies, this study assesses the prospective acceptability of and willingness to take digital pills among patients, the public, and health care professionals.

methodsParticipants were patients who were receiving long-term treatment for a chronic condition, public participants (both groups recruited from a representative sample), and health care professionals. Participants answered 5 open-ended questions regarding the acceptability of digital pills and 1 close-ended question regarding the willingness to take digital pills, which were developed in a preliminary qualitative study. We explored the 5 theoretical dimensions of acceptability by performing an abductive qualitative content analysis of all free-text responses. We assessed data saturation with mathematical models. We fitted a multivariate logistic regression model to identify the sociodemographic and health characteristics associated with the willingness to take digital pills.

resultsBetween January 29, 2020, and April 18, 2020, 767 patients, 1238 public participants, and 246 health care professionals provided 11,451 free-text responses. We identified 98 codes related to the acceptability of digital pills: 29 codes on perceived clinical effectiveness (eg, sensor safety cited by 66/2251 participants, 29.5%), 6 on perceived burden (eg, increased doctors' workload, 164/2251 participants, 7.3%), 25 on perceived ethicality (eg, policing, 345/2251 participants, 15.3%), 30 codes on perceived opportunity (eg, exclusively negative perception, 690/2251 participants, 30.7%), and 8 on affective attitude (eg, anger, 541/2251, 24%). Overall, 271/767 (35.3%) patients, 376/1238 (30.4%) public participants, and 39/246 (15.8%) health care professionals reported willingness to take digital pills. This willingness was associated with male sex (odds ratio 1.98, 95% CI 1.62-2.43) and current use of a connected device to record health settings (with a dose-response relationship).

conclusionsThe prospective acceptability of and willingness to take digital pills were limited by clinical and ethical concerns both at the individual and societal level. Our results suggest that digital pills should not be considered a mere change in the form of drug administration but a complex intervention requiring specific evaluation before extended use in clinical routine practice as well as an ethical and legal framework to ensure safe and ethical collection and use of health data through a patient-centered approach.

Indexed as

Health PersonnelMotivationHumansMaleProspective StudiesSmartphoneSurveys and Questionnairesacceptabilityadherenceclinical effectiveness researchdigital healthdigital pilldigital therapeuticsethicshealth technology assessmentingestible sensor

Identifiers

PMID35179509
PMCPMC8900921
OpenAlexW4212908431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.